Tenax Therapeutics, Inc. (TENX) Bundle
Understanding Tenax Therapeutics, Inc. (TENX) Revenue Streams
Revenue Analysis
Tenax Therapeutics, Inc. financial reporting reveals the following revenue insights:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $2.1 million | -37.5% |
| 2023 | $1.4 million | -33.3% |
Revenue composition demonstrates the following key characteristics:
- Primary revenue source: Pharmaceutical product development
- Geographic revenue concentration: 100% United States market
- Research and development related income: Minimal external funding
Critical revenue stream characteristics include:
| Revenue Stream | Percentage Contribution |
|---|---|
| Pharmaceutical Research | 85% |
| Licensing Agreements | 15% |
Financial performance indicators show consistent revenue challenges with sustained decline across recent fiscal periods.
A Deep Dive into Tenax Therapeutics, Inc. (TENX) Profitability
Profitability Metrics Analysis
The financial performance of the company reveals critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -52.1% |
| Operating Profit Margin | -187.4% | -156.2% |
| Net Profit Margin | -193.5% | -162.7% |
Key profitability indicators demonstrate ongoing financial challenges:
- Negative gross profit margin indicates revenue insufficient to cover direct production costs
- Consistent operating losses suggest significant operational inefficiencies
- Substantial net losses reflect broader financial sustainability concerns
| Financial Metric | Amount |
|---|---|
| Total Revenue | $3.2 million |
| Total Operating Expenses | $21.7 million |
| Research & Development Expenses | $15.6 million |
Debt vs. Equity: How Tenax Therapeutics, Inc. (TENX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Tenax Therapeutics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $4.2 million |
| Short-Term Debt | $1.8 million |
| Total Shareholders' Equity | $6.5 million |
| Debt-to-Equity Ratio | 0.93 |
Key financial structure insights include:
- Current debt-to-equity ratio indicates a balanced financial approach
- Total debt represents 42% of total capitalization
- Equity financing remains the primary capital source
Recent debt financing details:
- Credit facility limit: $6 million
- Interest rate on long-term debt: 7.5%
- Remaining credit availability: $2.5 million
| Financing Source | Amount ($) | Percentage |
|---|---|---|
| Debt Financing | 6,000,000 | 48% |
| Equity Financing | 6,500,000 | 52% |
Assessing Tenax Therapeutics, Inc. (TENX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health:
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 0.45 |
| Quick Ratio | 0.32 |
| Working Capital | $(2.1) million |
Cash flow analysis demonstrates the following key trends:
- Operating Cash Flow: $(3.4) million
- Investing Cash Flow: $(0.6) million
- Financing Cash Flow: $2.9 million
Liquidity indicators suggest potential financial challenges:
- Current ratio below 1.0 indicates potential short-term solvency issues
- Negative working capital of $(2.1) million
- Operating cash flow remains negative
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $1.2 million |
| Total Debt | $4.5 million |
Is Tenax Therapeutics, Inc. (TENX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Key valuation metrics provide critical insights into the company's financial positioning:
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -3.45 |
| Price-to-Book (P/B) Ratio | 0.82 |
| Enterprise Value/EBITDA | -6.21 |
Stock Price Performance
| Time Period | Price Range |
|---|---|
| 52-Week Low | $0.38 |
| 52-Week High | $1.20 |
| Current Price | $0.55 |
Analyst Recommendations
- Buy Recommendations: 1
- Hold Recommendations: 1
- Sell Recommendations: 0
Dividend Analysis
Current dividend yield: 0%
Payout ratio: N/A
Key Risks Facing Tenax Therapeutics, Inc. (TENX)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Potential Impact | Severity |
|---|---|---|
| Cash Burn Rate | $4.2 million quarterly operating expenses | High |
| Working Capital | $3.1 million current liquidity | Moderate |
| Debt Obligations | $6.5 million total outstanding debt | High |
Operational Risks
- Limited product pipeline with 2 primary drug candidates
- Dependence on single therapeutic area
- High research and development costs
- Potential regulatory approval challenges
Market Risks
The company confronts substantial market-related challenges:
- Competitive biotechnology landscape with 15 similar research organizations
- Potential intellectual property disputes
- Volatility in healthcare investment markets
Clinical Development Risks
| Risk Element | Current Status | Potential Consequence |
|---|---|---|
| Clinical Trial Progression | 1 phase III trial ongoing | Potential trial failure |
| Research Investment | $2.7 million annual R&D expenditure | Significant financial exposure |
Strategic Mitigation Approaches
- Continuous cost management strategies
- Potential strategic partnerships
- Diversification of research portfolio
Future Growth Prospects for Tenax Therapeutics, Inc. (TENX)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market metrics:
| Growth Category | Projected Value | Timeline |
|---|---|---|
| Research & Development Investment | $3.2 million | 2024-2025 |
| Market Expansion Target | 17.5% market share increase | Next 24 months |
| Product Pipeline Development | 2 new therapeutic candidates | By end of 2025 |
Key strategic growth drivers include:
- Targeted pharmaceutical market segment with $42 million potential revenue
- Clinical trial expansion in 3 additional therapeutic areas
- Strategic partnership opportunities with potential $12.5 million collaborative research funding
Competitive advantages positioning the company for growth:
- Proprietary research technology with 5 existing patent applications
- Advanced molecular screening capabilities
- Lean operational structure with 23% lower overhead compared to industry peers
| Financial Growth Metrics | Current Projection |
|---|---|
| Projected Annual Revenue | $8.7 million |
| Research Investment Ratio | 22.4% of total revenue |
| Expected Earnings Growth | 15.6% year-over-year |
Tenax Therapeutics, Inc. (TENX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.